101% Original
Lowest Price
Free Shipping

Epicephin 500mg IM Vial

EGP47

8 products sold in last 13 hours
Selling fast! Over 9 people have in their cart
28 people are viewing this right now
  • Check Mark Estimated Delivery : Same day
  • Check Mark Free Shipping & Returns : On all orders over 200 EGP
  • Visa Card
  • MasterCard
Guaranteed Safe And Secure Checkout

Medication Name: Epicephin 500mg IM Vial

Active Ingredient:
Ceftriaxone 500 mg

Pharmacological Class:
Third-generation cephalosporin antibiotic

Indications:
Used for the treatment of various bacterial infections such as:

  • Respiratory tract infections (bronchitis, pneumonia)

  • Urinary tract infections

  • Skin and soft tissue infections

  • Bone and joint infections

  • Abdominal infections

  • Gonorrhea

  • Meningitis

  • Septicemia and other systemic infections

Mechanism of Action:
Ceftriaxone inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), resulting in disruption of cell wall formation and bacterial death.

Dosage:

  • Adults: 500 mg to 1 g once daily, or divided every 12 hours depending on infection type and severity.

  • Children: 50–75 mg/kg/day (maximum 2 g/day).

  • Administered intramuscularly (IM) or intravenously (IV) as prescribed.

  • For IM use, reconstitute the vial with sterile water or 1% lidocaine solution to reduce injection discomfort.

Precautions:

  • Contraindicated in patients with cephalosporin hypersensitivity.

  • Use with caution in those allergic to penicillins.

  • Dose adjustments may be necessary in renal or hepatic impairment.

  • Avoid co-administration with calcium-containing IV solutions, particularly in neonates.

Possible Side Effects:

  • Pain or irritation at the injection site

  • Nausea, vomiting, or diarrhea

  • Skin rash or itching

  • Headache or dizziness

  • Rarely: Allergic reactions, colitis, or hematologic abnormalities

Reviews

There are no reviews yet.

Be the first to review “Epicephin 500mg IM Vial”

Your email address will not be published. Required fields are marked *